SensoLyte® Green Glutaminyl Cyclase Activity Assay - Industry's First
SensoLyte Green Glutaminyl Cyclase Assay Kit

SensoLyte® Green Glutaminyl Cyclase Activity Assay Kit (Cat# AS-72230)

Line
Industry's First
Line
✓ Sensitive - detects as low as 1.5 ng/mL of active Glutaminyl Cyclase
Line
✓ Long wavelength, green fluorimetric assay kit (Ex/Em=490/520 nm) –     minimal autofluorescence
Line
✓ Fluorescence signal proportional to enzyme activity
Line
✓ Convenient two-step homogeneous assay format
Line
✓ Assay can be completed in 1.5 hours
Line
✓ Validated with human and plant Glutaminyl Cyclase
Line
✓ Validated with human biological samples (Figure 2)
Line
✓ Adaptable to high throughput screening (HTS)
Line
inhibitor
Figure 1.1-Benzyl-Imidazole inhibition of Glutaminyl Cyclase activity measured with SensoLyte® Green Glutaminyl Cyclase Activity Assay Kit.
inhibition
Figure 2. Glutaminyl Cyclase Activity in Human Body Fluids. Human cerebrospinal fluid (CSF) and saliva were diluted 2.5-fold using assay buffer ±Glutaminyl Cyclase inhibitor and were tested for the enzyme activity using SensoLyte® Green Glutaminyl Cyclase Assay Kit.

 

Product Catalog #

SensoLyte® Green Glutaminyl Cyclase Activity Assay *Fluorimetric* NEW

AS-72230

AnaSpec is pleased to announce the release of the first commercially available 96-well format fluorimetric assay for measuring Glutaminyl Cyclase (QC) activity - the SensoLyte® Green Glutaminyl Cyclase Activity Assay Kit.

 

Glutaminyl cyclase (QC), an enzyme found in animals and plants, catalyzes the cyclization of N-terminal Glutamine, and to a lesser extent Glutamate, to pyroglutamate.1 This post-translational modification to pyroglutamate, present in many biologically active peptides and proteins, protects against degradation by aminopeptidases and in many cases determines functionality of protein or peptide.2-7

 

Pyroglutamate modification sometimes may lead to negative side effects. pGlu (or pE) modified β-amyloid peptides (pGlu-Aβ) aggregate much faster than non-pyroglutamic Aβ and form toxic oligomers that may damage neurons.8-10 CCL2 (monocyte chemoattractant protein 1, MCP-1), implicated in a number of diseases has in its mature form an N-terminal pGlu. This modification protects it against aminopeptidase degradation, and improves receptor activation and signal transduction in vitro.11 Increased levels of pE-CCL2 has been implicated in thyroid carcinoma proliferation and metastasis,12 and atherosclerosis,11 and other inflammatory disorders.11 Thus, Glutaminyl Cyclase (QC) inhibitors are attractive drug candidates.

inhibition
Glutaminyl
Figure 3. SensoLyte® Green Glutaminyl Cyclase Assay Principle.
 

RELATED PRODUCTS:

ß-Amyloid Peptides - Wide Collection
Anti-ß-Amyloid Antibodies - monoclonal and polyclonal antibodies
SensoLyte® Assay Kits for Alzheimer's and Parkinson's Disease Research
SensoLyte®Amyloid Degrading Protease Assay Kits
Tau Products - Antibodies, Recombinant Proteins and Peptides


References:

  1. Schilling, S. et al. Biol Chem 389, 983 (2008).
  2. Kumar, A. et al. Curr Sci 102, 288 (2012).
  3. Castaldo, C. et al. PLOS One 8, 1 (2013).
  4. Booth, ER. et al. BMC Biol 2, 1 (2004).
  5. Schilling, S. et al. Biol. Chem 384, 1583 (2003).
  6. Huang, W-L. et al. J. Mol. Biol. 401, 374 (2010).
  7. Gontsarova, A. et al. Clin Chim Acta 389, 152 (2008).
  8. Sullivan, PC. et al. Neur Lett 505, 109 (2011).
  9. Wirths, O. et al. J Biol Chem 285, 41517 (2010).
  10. Hartlage-Rubsamen, M. et al. Acta Neuropathol 121, 705 (2011).
  11. Cynis, H. et al. EMBO Mol Med 3, 545 (2011).
  12. Kehlen, A. et al. Endocr Relat Cancer 20, 79 (2012).